Abstract
Human adenoviruses can cause serious disseminated infections including death in immunosuppressed patients, especially pediatric allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. There are no drugs approved to treat such infections. Cidofovir is used intravenously in many transplant clinics, probably with some effect, but controlled trials have not been completed. Cidofovir is an acyclic nucleoside phosphonate analog of cytidine monophosphate. Following conversion to its diphosphate form within cells, cidofovir is a preferred substrate for the adenovirus DNA polymerase, leading to viral DNA chain termination. Problems with cidofovir include poor cellular uptake and nephrotoxicity. Brincidofovir, a lipid-linked derivative of cidofovir which is active against five families of double-stranded DNA viruses, represents a major advance in anti-adenovirus therapy. It is administered orally, taken up readily by cells followed by release of cidofovir within cells, and is not nephrotoxic. Brincidofovir, under development by Chimerix, Inc., is being evaluated against adenovirus infections in transplant patients including allo-HSCT patients in a phase III clinical trial (AdVise Study). Preliminary results indicate that brin...Continue Reading
References
Jan 6, 2005·The Journal of Infectious Diseases·Caroll B HartlineEarl R Kern
May 21, 2008·Proceedings of the National Academy of Sciences of the United States of America·Karoly TothWilliam S M Wold
Feb 12, 2010·Leukemia·T LionS Matthes-Martin
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Diana F FlorescuCharles van der Horst
May 1, 2013·PloS One·René GeyereggerGerhard Fritsch
Feb 13, 2014·Immunological Reviews·Ann M LeenMalcolm K Brenner
Jun 9, 2014·Current Infectious Disease Reports·Uriel SandkovskyDiana F Florescu
Jul 2, 2014·Clinical Microbiology Reviews·Thomas Lion
Aug 15, 2014·Expert Review of Anti-infective Therapy·Diana F Florescu, Megan A Keck
Sep 17, 2014·Antimicrobial Agents and Chemotherapy·Baoling YingWilliam S M Wold
Dec 3, 2014·Antiviral Research·Ann E TollefsonKaroly Toth
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gertjan LugthartArjan C Lankester
Jan 27, 2015·Blood·Judith FeuchtTobias Feuchtinger
Mar 26, 2015·Viruses·Karoly TothWilliam S M Wold
Citations
Nov 14, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bradley J Gardiner, David R Snydman
Aug 3, 2016·Transplant Infectious Disease : an Official Journal of the Transplantation Society·S VoigtJ-S Kühl
Oct 25, 2016·Seminars in Nephrology·Dana J Hawkinson, Michael G Ison
Apr 21, 2017·Expert Opinion on Pharmacotherapy·Shellee A GrimNina M Clark
Jul 12, 2017·Bone Marrow Transplantation·J-S ClaveauJ Roy
Feb 20, 2018·Pharmacotherapy·Nimisha SulejmaniMayur Ramesh
Dec 22, 2016·F1000Research·Lakshmi GanapathiOfer Levy
Jul 20, 2017·Allergy·M R EdwardsUNKNOWN EAACI Anti-infectives in Asthma and Asthma Exacerbations Task Force
Oct 5, 2018·Virology Journal·Sebastien KenmoeRichard Njouom
Jan 24, 2020·Case Reports in Infectious Diseases·T Van GenechtenC Dhooge
Apr 8, 2020·Clinical Ophthalmology·Bisant A LabibDeGaulle I Chigbu
Jun 14, 2017·Viruses·Karoly TothWilliam S M Wold
May 10, 2017·Expert Review of Anti-infective Therapy·Matthew W McCarthy, Thomas J Walsh
Aug 27, 2017·Viruses·Victoria A Olson, Sergei N Shchelkunov
Jul 12, 2020·Disease Models & Mechanisms·Rong LiKaroly Toth
Dec 31, 2019·Clinical Infection in Practice·Tom WingfieldRichard Wenstone
Sep 13, 2020·Antiviral Research·Flavia M MicheliniLaura E Alché
Feb 5, 2021·MSphere·Christina L HutsonVictoria A Olson
Mar 8, 2021·Vaccine·Jerome CustersUNKNOWN Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
Aug 12, 2021·Indian Journal of Nephrology·Harshavardhan T SanathkumarEdwin M Fernando
Aug 28, 2021·Antibiotics·Zhenwei YuGang Han